Literature DB >> 18087853

Assessment of clinical severity in Dupuytren's disease.

A Bayat1, E J Cunliffe, D A McGrouther.   

Abstract

Every clinician should be aware of the key features in the history and examination of the patient with Dupuytren's disease to know when surgical referral is appropriate and to inform the patient about causation and prognosis. This article outlines the most relevant questions to ask and provides a systematic approach to the clinical examination.

Entities:  

Mesh：

Year:  2007        PMID： 18087853     DOI： 10.12968/hmed.2007.68.11.27683

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN： 1750-8460            Impact factor:   0.825


  14 in total

1.  Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren's disease.

Authors:  R Arora; P Kaiser; T-J Kastenberger; G Schmiedle; S Erhart; M Gabl
Journal:  Oper Orthop Traumatol       Date:  2015-12-18       Impact factor: 1.154

2.  Connective tissue diseases: A nonsurgical therapy for Dupuytren disease.

Authors:  Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-01       Impact factor: 20.543

3.  Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy.

Authors:  Syed Amir Iqbal; Christopher Manning; Farhatullah Syed; Venkatesh Kolluru; Mike Hayton; Stewart Watson; Ardeshir Bayat
Journal:  Stem Cells Dev       Date:  2011-07-19       Impact factor: 3.272

4.  The modified Patient and Observer Scar Assessment Scale: a novel approach to defining pathologic and nonpathologic scarring.

Authors:  Regina M Fearmonti; Jennifer E Bond; Detlev Erdmann; L Scott Levin; Salvatore V Pizzo; Howard Levinson
Journal:  Plast Reconstr Surg       Date:  2011-01       Impact factor: 4.730

Review 5.  Scientific understanding and clinical management of Dupuytren disease.

Authors:  Barbara Shih; Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

6.  The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease.

Authors:  Alexis Thomas; Ardeshir Bayat
Journal:  Ther Clin Risk Manag       Date:  2010-11-04       Impact factor: 2.423

7.  Reversal of TGF-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts.

Authors:  Latha Satish; Phillip H Gallo; Mark E Baratz; Sandra Johnson; Sandeep Kathju
Journal:  BMC Musculoskelet Disord       Date:  2011-05-25       Impact factor: 2.362

8.  Prevalence, incidence, and treatments of Dupuytren's disease in the United States: results from a population-based study.

Authors:  Dana Britt Dibenedetti; Dat Nguyen; Laurie Zografos; Ryan Ziemiecki; Xiaolei Zhou
Journal:  Hand (N Y)       Date:  2010-11-16

9.  Dupuytren's Disease: Review of the Current Literature.

Authors:  Morsi Khashan; Peter J Smitham; Wasim S Khan; Nicholas J Goddard
Journal:  Open Orthop J       Date:  2011-07-28

10.  Recapitulation of fibromatosis nodule by multipotential stem cells in immunodeficient mice.

Authors:  Jung-Pan Wang; Yun-Ju Hui; Shih-Tien Wang; Hsiang-Hsuan Michael Yu; Yi-Chao Huang; En-Rung Chiang; Chien-Lin Liu; Tain-Hsiung Chen; Shih-Chieh Hung
Journal:  PLoS One       Date:  2011-08-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.